Nasdaq:CPRX

Company to Expand R&D Focus for Pipeline Growth to include Earlier Stage Programs and Validated Technology Platforms Firdapse® 2020 Net

– Firdapse® Third Quarter Net Revenues of $29.2 Million – Company Ends Third Quarter with $127.1 Million in Cash and

CORAL GABLES, Fla., Nov. 02, 2020 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused

CORAL GABLES, Fla., Nov. 02, 2020 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused

CORAL GABLES, Fla., Nov. 02, 2020 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused

CORAL GABLES, Fla., Oct. 19, 2020 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused

Issued Patent is the First Covering Firdapse® CORAL GABLES, Fla., Oct. 06, 2020 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst)

Issued Patent is the First Covering Firdapse® CORAL GABLES, Fla., Oct. 06, 2020 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst)

CORAL GABLES, Fla., Sept. 29, 2020 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that the federal

Notice of Application for Judicial Review Filed Today in the Federal Court of Canada CORAL GABLES, Fla., Aug. 26, 2020